# KIMMTRAK (tebentafusp) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tebentafusp

> The FDA approved KIMMTRAK (tebentafusp), sponsored by Immunocore Holdings plc (IMCR), on Apr 2022 for unresectable or metastatic uveal melanoma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KIMMTRAK (tebentafusp) |
| Codes |  |
| Sponsor | Immunocore Holdings plc (IMCR) https://sec-api.dev/companies/imcr/catalysts |
| Indications | unresectable or metastatic uveal melanoma, cancer, infectious diseases and autoimmune diseases, today, previously treated advanced cutaneous melanoma, [Advanced Melanoma](https://sec-api.dev/indications/advanced-melanoma) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Apr 2022: FDA approval

- Status: completed, approved. Date confidence: month. Indication: unresectable or metastatic uveal melanoma.
- First seen 2025-02-26, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001671927-25-000018): "In January and April 2022, the Company received approval from the U.S. Food and Drug Administration ("FDA") and European Commission ("EC"), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma." https://www.sec.gov/Archives/edgar/data/1671927/000167192725000018/imcr-20250930.htm
- SEC Form 10-Q (accession 0001671927-25-000014): "In January and April 2022, the Company received approval from the U.S. Food and Drug Administration ("FDA") and European Commission ("EC"), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma." https://www.sec.gov/Archives/edgar/data/1671927/000167192725000014/imcr-20250630.htm
- SEC Form 10-K (accession 0001671927-25-000006): "In January and April 2022, the Company received approval from the U.S. Food and Drug Administration ("FDA") and European Commission ("EC"), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma and has subsequently received approvals in further territories, and the Company continues to launch and seek approvals in additional territories." https://www.sec.gov/Archives/edgar/data/1671927/000167192725000006/imcr-20241231.htm

### late 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: cancer, infectious diseases and autoimmune diseases, today.
- First seen 2026-01-09, last confirmed 2026-09-14.
- Press release filed with the SEC (EX-99) (accession 0001671927-26-000026): "Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297)." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/pressrelease-tebexamenroll.htm
- Press release filed with the SEC (EX-99) (accession 0001671927-26-000026): "The Company expects to be able to share topline data as early as the end of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/pressrelease-tebexamenroll.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-006721): "TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026" https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm
- SEC Form 10-Q (accession 0001671927-26-000022): "Enrollment in the registrational Phase 3 TEBE-AM trial, evaluating tebentafusp as monotherapy and in combination with pembrolizumab, versus a control arm in patients with previously treated advanced cutaneous melanoma, is nearing the target of 540 patients, with topline data that could come as early as the end of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000022/imcr-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-000780): "Enrolling three Phase 3 trials across multiple melanoma indications - TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026" https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/ef20062561_ex99-1.htm

### Q2 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-06, last confirmed 2026-11-06.
- Press release filed with the SEC (EX-99) (accession 0001671927-26-000034): "Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients - Topline overall survival data expected second quarter of 2027" https://www.sec.gov/Archives/edgar/data/1671927/000167192726000034/pressrelease-q32026.htm
- Press release filed with the SEC (EX-99) (accession 0001671927-26-000034): "The trial is event-driven and topline overall survival data is expected in the second quarter of 2027." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000034/pressrelease-q32026.htm
- SEC Form 10-Q (accession 0001671927-26-000035): "The trial is event-driven and topline overall survival data is expected in the second quarter of 2027." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000035/imcr-20260930.htm

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Advanced Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05549297 (Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Immunocore Ltd." https://clinicaltrials.gov/study/NCT05549297

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Advanced Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05549297 (Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Immunocore Ltd." https://clinicaltrials.gov/study/NCT05549297

## Same indication

- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab) (AGEN)
- [Brenetafusp](https://sec-api.dev/pdufa/brenetafusp) (IMCR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tebentafusp.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KIMMTRAK (tebentafusp) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tebentafusp

```bibtex
@misc{secapidev_pdufa_tebentafusp_20261116,
  title        = {KIMMTRAK (tebentafusp) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tebentafusp}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tebentafusp_20261116","title":"KIMMTRAK (tebentafusp) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tebentafusp","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
